Acorda completes enrollment for phase III MS trial

The study, which is based on a special protocol assessment issued by the FDA, is evaluating the safety and efficacy of Fampridine-SR in improving walking ability in people with MS.

The primary outcome measure for the study is an improvement in walking ability; secondary outcomes include measurements of leg strength and muscle spasticity. Data from this trial are expected in the third quarter of 2006.

Acorda also announced that it has expanded its in-house, specialty sales force for Zanaflex capsules from 14 to 32. The increased sales force will continue to focus on the neurology and physical medicine and rehabilitation markets. Zanaflex capsules are a short-acting drug approved for the management of spasticity.

Acorda is a commercial-stage biopharmaceutical company focused on therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.